Press Releases
Click to see our news releases about special projects and other announcements.
Read MoreMedia Requests
Journalists: We are at your service. Please contact us with your request.
ConnectISB News
Andy Hill CARE Fund Awards $100,000 to ISB's Dr. Wei Wei
To advance research at the intersection of COVID-19 and cancer, The Andy Hill CARE Fund has awarded ISB Assistant Professor Dr. Wei Wei a $100,000 grant to study chronic lymphocytic leukemia (CLL), one of the most commonly diagnosed leukemias in the Western world that mainly affects older individuals.
ISB Undergraduate Researcher Daniel Chen Earns Goldwater Scholarship
Daniel Chen, an undergraduate researcher in ISB’s Heath Lab and junior at the University of Washington, has been awarded a prestigious Goldwater Scholarship. Chen has been a key member of ISB’s COVID-19 Immune Response Study.
COVID-19 Outcome Disparities Across Racial/Ethnic Lines
ISB researchers and their collaborators looked at the electronic health records of nearly 630,000 patients who were tested for SARS-CoV-2, and found stark disparities in COVID-19 outcomes — odds of infection, hospitalization, and in-hospital mortality — between White and non-White minority racial and ethnic groups.
How Will Healthcare and Scientific Research Be Different in a Post-Pandemic World?
Providence President and CEO Dr. Rod Hochman joined ISB President and Professor Dr. Jim Heath for an hour-long conversation hosted by ISB and Town Hall Seattle about how healthcare and science will be different in a post-pandemic world.
Drs. Anthony Fauci, Lee Hood Talk COVID-19, Vaccines, Future of Research, More
NIAID Director Dr. Anthony Fauci sat down for a conversation with ISB’s Dr. Lee Hood. The renowned scientists spoke about the importance of basic research, the extraordinary speed of COVID research, the efficacy of mRNA vaccines on COVID-19, lessons learned from the COVID-19 pandemic, and much more.
COVID-19 Immune Response Study Could Lead to More Effective Treatments
Findings from the ISB-Swedish COVID-19 Immune Response Study suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The team studied 139 patients and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.
ISB Builds Digital Platform for COVID-19 Research Study – and Beyond
In a multi-institutional study of a highly infectious disease like COVID-19, paperless consent for study participants is critical. One component of the COVID-19 Immune Response Study is a recruitment website with an IRB-approved and HIPAA-compliant electronic consent platform for enrolling patients.
Molecular Biologist Dr. Sui Huang: We Should All Be Wearing Masks
ISB’s Dr. Sui Huang has been a powerful voice in a growing chorus contending that masks are an effective tool to stop the spread of COVID-19. Huang calls guidelines from the CDC and other public health agencies “unfortunate,” as they sweep aside a potentially powerful measure that could help “flatten the curve.”
Merck, ISB, Swedish Collaborate In Trial to Understand, Treat COVID-19
ISB and Swedish Medical Center launched a study to follow hundreds of patients who contract COVID-19 to learn why those infected have drastically different outcomes. “Each of the COVID-19 patients has a unique lesson to teach us about how the medical and scientific community can respond most effectively to this pandemic,” said ISB President Dr. Jim Heath, who co-leads the study.
ISB Statement Concerning the Ongoing Coronavirus Outbreak
ISB is committed to the health and safety of our research and administrative staff. Some of our scientists are conducting important COVID-19 research. Otherwise, ISB is adhering to Governor Jay Inslee’s stay-at-home orders. For the latest coronavirus information, please monitor the Centers for Disease Control and Prevention (CDC) webpage linked from this news item.